RLMD
Relmada Therapeutics, Inc. · Healthcare
Director Paul Edward Kelly sold $82K of Relmada Therapeutics, Inc.
Sold$82,203
$35.04Price
2,346Shares
−1%Stake
What RLMD did after the filing
- The stock from Wed, Feb 3 close, $34.47
- +3.0%
- S&P 500, same days
- +2.5%
Measured over 30 trading days, to the Mar 18 close.
Traded Mon, Feb 1. Filed Wed, Feb 3, 1:34 PM ET, during the session. Returns use the Feb 3 close and the Mar 18 close. Not investment advice.